Home > Insider Trading > Filing (0001209191-17-044266)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1685071	Dova Pharmaceuticals Inc.	DOVA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1494695	B Paul Manning	200 Garrett Street, Suite S Charlottesville VA 22902		Yes	No	Yes	No
1665309	Pbm Capital Investments, Llc	200 Garrett Street, Suite S Charlottesville VA 22902		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	100,000	$17.00	100,000	No	4	P	Direct
Common Stock	Acquisiton	2017-07-05	50,000	$17.00	1,783,226	No	4	P	Indirect	By LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	12,214,953	Indirect	By LLC

Footnotes

These shares are held by the Reporting Person together with his spouse as Joint Tenants with Right of Survivorship.
These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.